Omega-3 fatty acids and human health: why strong claims remain on fragile consensus

Future clinical practices and research should shift toward biomarker-guided and personalized ω-3 PUFAs intervention strategies with mandatory prerequisite knowledge about product quality, e.g. dietary supplements and ω-3 PUFAs rich/fortified foods, and baseline blood-based ω-3 PUFAs nutritional status. Standardized reporting of formulation, oxidation status, and participant baseline characteristics is essential to clarify dose-response relationships and optimize therapeutic efficacy of ω-3 PUFAs.